Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDRH Looks Ahead, And Behind, On Guidance Development

This article was originally published in The Gray Sheet

Executive Summary

The device center issued its standard "A list" and "B list" guidance priorities for fiscal year 2015, and unveiled plans to systematically reassess published guidance documents and seek technical feedback on future guidance topics.


Related Content

CDRH Sets Performance Goals To Reduce Draft Guidance Ambiguity
Clinical Labs Lawyer Up In Battle Over LDTs
Active Months Ahead For mHealth Regulatory Policymaking
Leap Ahead With EAP? FDA Proposes New Expedited PMA Pathway
510(k) Program, Companion Dx Among Top FDA Guidance Priorities For FY 2014





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts